Wolverine Trading’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Wolverine Trading’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-340	Closed	-$2.97K	–	5300
2020 Q2	$3K	Sell	340 -325	-49%	-$4.9K	﹤0.01%	4474
2020 Q1	$10K	Buy	+665	New	+$14.4K	﹤0.01%	4483
2018 Q4	–	Sell	-311	Closed	-$22K	–	5521
2018 Q3	$22K	Sell	311 -11	-3%	-$835	﹤0.01%	4796
2018 Q2	$31K	Hold	322	–	–	﹤0.01%	4986
2018 Q1	$31K	Buy	322 +2	+0.6%	+$343	﹤0.01%	4986
2017 Q4	$41K	Buy	+320	New	+$30K	﹤0.01%	4636
2017 Q2	–	Sell	-411	Closed	-$47.2K	–	5122
2017 Q1	$59K	Buy	+411	New	+$58.8K	﹤0.01%	3970
2016 Q3	–	Sell	-91	Closed	-$12.8K	–	5214
2016 Q2	$10K	Buy	+91	New	+$10.1K	﹤0.01%	3933

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's VIRX Position: Q3 2020 in Review

Wolverine Trading sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2020, closing a stake of 340 shares — an estimated $2.97K sold.

Wolverine Trading first reported a position in VIRX in Q2 2016 and held it in 8 quarters. The position peaked at $59K in Q1 2017. 28 funds tracked by Wall St. Rank hold VIRX as of Q3 2020.

Wolverine Trading reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Wolverine Trading sold 340 Viracta Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $2.97K.
Wolverine Trading first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2016 and held it in 8 quarters.
Wolverine Trading's Viracta Therapeutics, Inc. Common Stock position peaked at $59K in Q1 2017.
28 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Wolverine Trading's 13F filing for Q3 2020, filed 13 Nov 2020.